ResMed Inc. (RMD)

Executive Summary / Key Takeaways

• ResMed is executing a rare combination of structural margin expansion and ecosystem deepening, with gross margins surging 320 basis points year-over-year to 61.8% while simultaneously building an AI-driven digital health platform that competitors cannot replicate, creating a durable competitive advantage in a market where patient adherence is the ultimate prize.

• The GLP-1 "threat" has become a tangible tailwind: patients on these medications are 10-11% more likely to start CPAP therapy and demonstrate measurably higher resupply rates, directly addressing investor concerns while expanding the addressable patient funnel at a time when market penetration remains below 20% in developed markets.

• Philips' (PHG) prolonged absence from the device market has allowed ResMed to consolidate its leadership position, but the real moat isn't market share—it's the integrated ecosystem of myAir, AirView, and Brightree that creates data lock-in and switching costs, evidenced by mask sales growing 16% while devices grow 9%, driving higher-margin recurring revenue.

• Management's guidance for 62-63% gross margins in FY26, combined with a stepped-up share repurchase program exceeding $600 million, signals confidence in sustained operational leverage and a disciplined capital allocation shift toward returning cash while maintaining R&D investment in AI-enabled therapy solutions.

• The primary risks are execution-related rather than fundamental: patent litigation decisions due by July 2026 could impact product features, while the Australian tax audit presents a potential material liability, though the balance sheet's $753 million net cash position provides substantial cushion for any adverse outcomes.

Setting the Scene: The Sleep Apnea Market's Digital Transformation

ResMed Inc., founded in 1989 and incorporated in Delaware in 1994, has evolved from a medical device manufacturer into the architect of a global digital health ecosystem for sleep and breathing disorders. The company generates over $5 billion in annual revenue by selling continuous positive airway pressure (CPAP) devices, masks, and accessories, but the business model is increasingly about capturing and monetizing patient data across the entire care journey. This distinction transforms ResMed from a cyclical hardware company into a recurring-revenue platform with network effects.

The industry structure reveals why this positioning is powerful. Sleep apnea affects over 1 billion people globally, yet market penetration remains low: 15-20% in the United States, 10-15% in Europe, and under 5% in Asia-Pacific. A landmark study projects that by 2050, nearly 77 million U.S. adults will have sleep apnea, a 35% increase from 2020. This underpenetration is a structural problem of diagnosis, treatment initiation, and long-term adherence. Traditional CPAP therapy suffers from dropout rates as high as 50% in the first year, creating a leaky funnel that limits market growth.

ResMed's strategy directly addresses this friction. The company has built a vertically integrated ecosystem that starts with home sleep testing, flows through physician software, connects to cloud-enabled devices, and retains patients through digital coaching. Each touchpoint generates data that improves the entire system. When a patient uses Comfort Match, ResMed's FDA-cleared AI tool that recommends personalized CPAP settings, the algorithm learns from millions of therapy sessions, making the next patient's onboarding smoother and more effective. This creates a data flywheel that hardware-only competitors cannot replicate.

The competitive landscape underscores ResMed's differentiation. Philips, with 25-30% market share, remains distracted by its 2021 CPAP recall and subsequent litigation, having reserved an additional $630 million in 2026 for remediation costs. Fisher & Paykel (FPH) excels in humidification technology but lacks ResMed's integrated digital platform. Medtronic's (MDT) respiratory segment is a small part of a diversified conglomerate, while SomnoMed's (SOM) oral appliances serve a niche segment of CPAP-intolerant patients. ResMed's 55% global market share in flow generators is about being more embedded in the patient journey, with switching costs that rise as patients and providers invest in the ecosystem.

Technology, Products, and Strategic Differentiation: The AI-Powered Moat

ResMed's core technological advantage lies in its ability to transform raw therapy data into actionable insights that improve patient outcomes. The AirSense 11 device is a cloud-connected computer that streams data to AirView, where clinicians can monitor adherence remotely. This shifts the value proposition from selling a machine to ensuring therapy success, allowing ResMed to command premium pricing while reducing healthcare costs through better outcomes.

The recent launch of fabric-based masks exemplifies how product innovation drives margin expansion. These masks address the primary reason patients abandon CPAP therapy: discomfort. By using soft fabric instead of silicone, ResMed has created a differentiated product line that commands higher average selling prices while improving adherence rates. The 16% growth in masks and accessories versus 9% growth in devices in Q2 FY26 is the result of deliberate portfolio management that prioritizes high-margin, high-frequency replacement products. This mix shift is structural because masks require quarterly replacement while devices last 5-7 years.

The AI integration represents the next phase of differentiation. Comfort Match, launched in December 2025, uses machine learning to analyze patient breathing patterns and recommend optimal pressure settings within the myAir app. This is ResMed's first FDA-cleared AI-enabled medical device, which is significant because regulatory clearance creates a barrier to entry for software-only competitors. The Dawn AI assistant, rolled out in Australia in June 2025 and the U.S. in Q1 FY26, provides personalized coaching that has been shown to improve adherence by 20-30% in clinical studies. This is a patient retention tool that directly addresses the industry's biggest challenge.

The digital ecosystem's network effects become apparent when examining the data flows. AirView processed over 3 billion API calls per quarter in Q1 FY26, a 40% year-over-year increase. Each call represents a data exchange between ResMed's platform and healthcare providers, payers, or patients. This creates switching costs that compound over time. A sleep clinic that has integrated AirView into its workflow cannot easily switch to a competitor's device without disrupting its entire operational infrastructure. The Brightree and MEDIFOX DAN SaaS platforms extend this moat into the administrative layer, managing billing, inventory, and patient scheduling for out-of-hospital providers.

Research and development spending, at 6.4% of revenue, is targeted. ResMed focuses on three vectors: next-generation masks, cloud-connected devices, and digital health software with AI integration. This demonstrates capital discipline—unlike medtech peers that spread R&D across multiple therapeutic areas, ResMed concentrates its investment where it has proven competitive advantages. The result is a pipeline of innovations like the fingertip-sized NightOwl home sleep test that lower the barrier to diagnosis, expanding the funnel for device sales.

Financial Performance & Segment Dynamics: Margin Expansion as Evidence of Moat Strength

ResMed's Q2 FY26 results provide compelling evidence that the digital ecosystem strategy is translating into superior financial performance. Revenue grew 11% (9% constant currency) to $1.42 billion. The 320 basis point expansion in gross margin to 61.8% reflects manufacturing and logistics efficiencies, component cost improvements, and a favorable mix shift toward higher-margin masks and software. This demonstrates operational leverage that should persist as the company scales its U.S. manufacturing footprint.

The segment dynamics reveal a deliberate strategy to maximize lifetime value per patient. Sleep and Breathing Health revenue grew 12% to $1.26 billion, with masks and accessories surging 16% while devices grew 9%. This 7-point growth gap is economically significant because masks generate 60%+ gross margins and require quarterly replacement, creating a recurring revenue stream that smooths the device replacement cycle. The VirtuOx acquisition, completed in Q4 FY25, contributed to this growth, but even excluding VirtuOx, mask sales grew double-digits. This organic strength shows ResMed is gaining share in the most profitable part of the market.

Geographic performance highlights the company's global execution capability. U.S., Canada, and Latin America grew 11% to $835 million, with devices up 8% and masks up 16%. Europe, Asia, and other markets grew 12% reported (6% constant currency) to $421 million. The constant currency deceleration in international markets reflects macro headwinds, but the fact that ResMed can still deliver mid-single-digit growth in challenging environments demonstrates geographic diversification. The new manufacturing facility in Calabasas, California, which doubles U.S. capacity, will further insulate the company from supply chain disruptions and potential tariff impacts.

The Residential Care Software segment, while smaller at $167 million in Q2 FY26, serves a critical strategic function. Growth of 7% (5% constant currency) appears modest, but management is actively managing the portfolio, divesting lower-margin services businesses while investing in high-growth verticals like MEDIFOX DAN in Germany. This matters because RCS isn't just a revenue line—it's the connective tissue that makes ResMed's devices stickier. Brightree's integration with over 1,000 home medical equipment providers creates a distribution and data advantage that competitors cannot easily replicate.

Cash flow generation remains robust, with $340 million in operating cash flow in Q2 FY26 and $797 million for the first half of FY26. This funds both growth investments and capital returns without straining the balance sheet. The company ended the quarter with $1.4 billion in cash and $753 million in net cash, providing flexibility for the $600+ million share repurchase program and the quarterly dividend, which was increased 13% for FY26. The decision to accelerate buybacks while maintaining R&D investment signals management's confidence that the stock offers attractive returns relative to internal investment opportunities.

Outlook, Management Guidance, and Execution Risk

Management's FY26 guidance reveals a company operating from a position of strength. The gross margin target of 62-63% represents a structural step-up from historical levels in the high-50s. This is the result of multi-year investments in manufacturing automation, supply chain optimization, and product mix management. The commitment to annual gross margin improvement through 2030 suggests a durable competitive advantage in operational excellence that will continue to drive earnings leverage.

SG&A expenses at 19-20% of revenue and R&D at 6-7% demonstrate disciplined capital allocation. The 15% increase in SG&A in Q2 FY26 reflects deliberate investments in demand generation, including direct-to-consumer campaigns and Continuing Medical Education programs that have reached 35,000 unique clinicians. This is a leading indicator of future growth—77% of clinicians completing CME courses report intending to change their clinical practice related to sleep apnea. The ROI on these marketing investments is measurable in the 16% mask growth rate, which drives recurring revenue.

The GLP-1 narrative represents a critical inflection in investor perception. For months, the market worried that weight-loss drugs would reduce sleep apnea prevalence and CPAP demand. ResMed's data refutes this: patients on GLP-1s are not only more likely to start CPAP therapy but also show 3% higher resupply rates at one year and 6% higher at three years. This transforms a perceived headwind into a tangible tailwind. As GLP-1s bring more motivated patients into the healthcare system, ResMed's integrated ecosystem is positioned to capture them earlier in the diagnosis funnel.

The competitive landscape is evolving, but ResMed's positioning appears increasingly defensible. Philips' CEO has indicated a potential return to the U.S. device market, but ResMed's advantages—smaller, quieter, more connected, more intelligent devices—are sustainable. The ecosystem of myAir, AirView, and Brightree is difficult to match and competitors struggle to compete across the board on that. This is reflected in the market share gains and margin expansion.

Execution risks center on three areas: the patent litigation timeline, the Australian tax audit, and the pace of RCS portfolio optimization. The PTAB decisions on Cleveland Medical Devices' patents, expected by July 2026, could impact ResMed's mask technology if the outcome is unfavorable. However, with 9,500+ patents in its portfolio, ResMed has defensive IP to negotiate cross-licenses or design around any adverse rulings. The Australian tax audit for 2018 could result in material adjustments, but the $753 million net cash position provides a buffer.

Risks and Asymmetries: What Could Break the Thesis

The most material risk to ResMed's investment thesis is regulatory and legal exposure. The patent infringement litigation with Cleveland Medical Devices and Fractus, S.A. represents a binary outcome. If the PTAB upholds the patents and ResMed cannot secure a favorable license, it may face restrictions on key mask features or royalty payments that could compress gross margins by 100-200 basis points. This is significant because masks represent the highest-margin, most recurring portion of the business.

The whistleblower complaint unsealed in December 2025, alleging False Claims Act violations related to CPAP sales to the VA, presents another legal wildcard. While ResMed has not been served, the existence of the complaint creates headline risk and potential distraction for management. The DOJ's decision on whether to intervene will be a key catalyst. Government contracts represent a meaningful portion of U.S. revenue, and any settlement could involve penalties and corporate integrity agreements that constrain sales practices.

Tax policy changes represent a structural headwind. The effective tax rate increased from 18% to 21.1% in Q2 FY26 due to Pillar Two global minimum tax legislation effective July 1, 2025. While management has guided to a 21-23% range for FY26, further international tax harmonization could push rates higher, reducing net income growth even if operational performance remains strong.

On the competitive front, Philips' eventual return to the U.S. device market is inevitable. While ResMed has gained share during the recall period, Philips retains strong brand recognition and hospital relationships. The risk is that increased competition could pressure ASPs and force higher SG&A spending to defend market position. ResMed's 19.6% SG&A ratio in Q2 FY26 already reflects increased marketing investment. If competitive intensity escalates, this ratio could drift higher, offsetting some of the gross margin gains.

The supply chain remains a vulnerability. The new Calabasas manufacturing facility and Greenwood distribution center reduce dependence on Asian suppliers, but semiconductor shortages and logistics disruptions could still impact device production. The company's ability to maintain 62%+ gross margins depends on continued component cost improvements and manufacturing efficiencies. Any reversal in these trends—due to inflation, tariffs, or capacity constraints—would pressure the margin expansion story.

Valuation Context: Pricing a High-Quality Compounder

At $225.99 per share, ResMed trades at 22.4x trailing earnings and 18.6x price-to-free-cash-flow. These multiples appear reasonable for a company delivering 11% revenue growth, 320 basis points of gross margin expansion, and 25.7% return on equity. The enterprise value of $32.4 billion represents 16.0x EBITDA, a premium to medtech peers but justified by superior growth and margins.

The balance sheet quality supports the valuation. With net cash of $753 million and debt-to-equity of just 0.13, ResMed has the financial flexibility to weather legal challenges, invest in growth, and return capital to shareholders simultaneously. The 1.06% dividend yield has grown consistently, and the $600+ million buyback program represents meaningful capital return. Management's view of the stock as attractively valued relative to internal investment opportunities is a key signal for investors.

Comparing ResMed to peers highlights its premium positioning. Philips trades at 24.5x earnings but with 45% gross margins and 10.7% operating margins—below ResMed's 61.5% and 35.2%. Fisher & Paykel's metrics are influenced by its smaller scale and geographic concentration. Medtronic's diversified portfolio trades at 24.1x earnings but with lower growth in its respiratory segment. ResMed's valuation premium reflects its pure-play focus, superior margins, and digital ecosystem moat.

The free cash flow yield of approximately 5.4% (based on $1.66 billion in TTM FCF) provides a floor for valuation. Even if growth were to slow to mid-single digits, the company's ability to convert 95% of operating cash flow to free cash flow demonstrates exceptional capital efficiency. ResMed can self-fund growth, return capital, and maintain its dividend without relying on external financing—a critical attribute in an uncertain macro environment.

Conclusion: A Compounder at an Inflection Point

ResMed's investment thesis hinges on the convergence of operational excellence and digital ecosystem expansion. The 320 basis points of gross margin expansion in Q2 FY26 is the manifestation of a decade-long strategy to vertically integrate manufacturing, optimize the supply chain, and shift the product mix toward high-margin, recurring-revenue masks and software. This operational leverage, combined with the GLP-1 tailwind that is bringing more motivated patients into the system, creates a durable growth algorithm that can deliver high-single-digit revenue growth and double-digit earnings growth for years.

The competitive moat has evolved beyond market share in devices. ResMed's integrated ecosystem of diagnostics, devices, masks, and digital health software creates data lock-in and switching costs that competitors cannot easily replicate. The real advantage is that ResMed's platform becomes more valuable to patients and providers with each additional data point. The AI-powered tools like Comfort Match and Dawn are patient retention engines that directly address the industry's adherence problem, potentially expanding the effective market size by improving therapy continuation rates.

The primary risks are legal and regulatory, not competitive or operational. Patent litigation decisions in July 2026 and the Australian tax audit represent binary outcomes that could impact margins and cash flow, though the strong balance sheet provides cushion. Execution risk in the RCS segment is manageable given the portfolio management actions underway.

For investors, the key variables to monitor are the sustainability of gross margin expansion beyond FY26, the pace of GLP-1 patient conversion, and the outcome of patent litigation. If ResMed can maintain 62%+ gross margins while growing the top line at 8-10%, the current valuation will prove attractive for long-term holders. The company's ability to compound capital at 25%+ ROE while returning cash to shareholders positions it as a high-quality defensive growth stock in an increasingly volatile healthcare landscape. The story is about building an unassailable position in a market that remains dramatically underpenetrated.